US · Healthcare · Biotechnology
EPS came in at -0.40 against a street estimate of -0.52 — a beat of 23.1%.
Analysts rate Damora Therapeutics, Inc. a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $46.89.
| Fund | Stake |
|---|---|
| FMR Inc | 14.96% |
| venBio Select Advisor LLC | 6.13% |
| BlackRock Inc | 5.12% |
| Viking Global Investors LP | 3.74% |
| Remedium Capital Partners, LLC | 3.31% |
| COMMODORE CAPITAL LP | 3.14% |
| BRAIDWELL LP | 2.62% |
| Bellevue Group AG | 2.62% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Damora Therapeutics is a biotechnology company developing therapies for hematological malignancies, with a current focus on antibo | 2026-11-04 |
| Quarterly report · Q2 2026 DAMORA THERAPEUTICS, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $540.5 million as of June 30, 2026 (up from $257.6 million at D | 2026-08-10 |
| Material agreement · Q3 2026 DAMORA THERAPEUTICS, INC. - 8-K FILING SUMMARY HEADLINE NUMBERS • Company: Damora Therapeutics, Inc., trades under ticker DMRA on Nasdaq Capital Mar | 2026-07-20 |
| Shareholder vote results · Q2 2026 DAMORA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 17, 2026 with 55,009,938 shares represented in person or by prox | 2026-06-17 |
| Quarterly report · Q1 2026 DAMORA THERAPEUTICS, INC. – 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash position: $532.9 million as of March 31, 2026 (up from $257.6 million at | 2026-05-12 |
| Board / officer change · Q2 2026 DAMORA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • CFO Departure Effective: May 1, 2026 • New CFO Appointment: Brian Burkavage (age 43), pro | 2026-05-04 |
| Proxy statement · Q2 2026 DAMORA THERAPEUTICS, INC. — 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 (Election of Directors): Vote to elect Mi | 2026-04-29 |
| Current report · Q2 2026 DAMORA THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • No financial results, revenue figures, or numerical performance metrics disclosed in this | 2026-04-20 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 25 effective Aug 30, 2024 | 2024-08-30 |
| Announcement | Date |
|---|---|
| Warrant issuance under antibody discovery and option agreement with Paragon Therapeutics Galecto, Inc. issued a warrant to Paramora Holding LLC allowing purchase of up to 628,302 shares of common stock. The warrant was issued on December 31, 2025, and expires on December 31, 203 | 2026-01-06 |
| Merger agreement approved; stockholder meeting scheduled for conversion and redomicile The company completed a merger with Damora and is now seeking stockholder approval for three key proposals: (1) converting Series B and C Preferred Stock into Common Stock to comply with Nas | 2025-11-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Damora Therapeutics, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.